Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Eli Lilly NYSE:LLY said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's OMXCOP:NOVO_B Ozempic pill in adults with type 2 diabetes, citing data from existing studies.The findings were based on an indirect comparison of L…